Abstract: Treatment for alleviating ischemia-reperfusion injury which has minimized risk of side effects and which can suppress neutrophilic infiltration and activation of platelets during ischemia reperfusion comprises administration by inhalation of a mixed gas comprising 21%-98% oxygen, 0.1%-4% hydrogen, 40-80 ppm nitrogen monoxide, and a remainder of inert gas such as nitrogen or helium to a patient undergoing reperfusion from immediately before the start of ischemia reperfusion until shortly after the start of reperfusion.

Abstract: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

Abstract: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

Abstract: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility active agent and such polymers, the polymers provide increased aqueous concentrations and/or improved physical stability of the active agent.

Abstract: The invention relates to a composition comprising at least one water-dispersible wax and at least one oil-dispersible micronized wax which, if desired, can be prepared at room temperature.

Abstract: The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (?9-THC) and other cannabinoid medicinal substances are decarboxylated through a chemical reaction facilitated by a cofactor. The amount of medicinal cannabis decarboxylated will be directly proportional to the amount of cofactor used. Use a small amount of the cofactor and only some of the medicinal cannabis contained in raw cannabis will be converted from an acidic form into a non-acidic form. Use a large amount of the cofactor and most or all of the medicinal cannabis will be decarboxylated. The reaction is proportional to the molar mass of cofactor.

Abstract: According to the present invention, there are provided a food and a food additive obtained using an alkaline decomposition product of a hop extract, and an agent for suppressing fat accumulation or for suppressing weight gain comprising the same as an active ingredient.

Abstract: A biomaterial mass is inserted through a punctum into a canaliculus in the lacrimal outflow system with a syringe. The mass has an outer cross section that is less than the inner cross section of the canaliculus. The mass absorbs liquid to swell to form a lacrimal filler or sealing mechanism. The lacrimal filler has an external cross section that conforms to the internal cross section of the canaliculus and a soft outer surface relative to the surrounding tissues to prevent erosion of the canaliculus lining. The lacrimal filler forms an occlusion that prevents the outflow of liquid through the lacrimal outflow system to retain tears within the eye to maintain eye lubrication and wetness. The mass and syringe are provided in kit with a rubber stopper and, optionally, a punctal dilator, an injecting catheter, and an enzyme for dissolving or degrading the lacrimal filler at a later time.

Abstract: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts thereof, b2) specific formaldehyde donors, b3) specific isothiazolinones, b4) specific paraben esters and the salts thereof, and b5) specific pyridones and the salts thereof. The liquid compositions are suitable for the production of cosmetic, dermatological or pharmaceutical products.

Abstract: The present invention relates to a pharmaceutical combination for the treatment of renal failure in pets, caused by various diseases or ineffective to traditional renal therapy or renal replacement therapy thereby incapable of restoring health. The pharmaceutical combination of the present invention is administered by subcutaneous injection to pets in need thereof, with various advantages including simple use, no requirement for surgery, hospitalization and/or fluid infusion, faster recovery of health status, reduced medical costs, significantly improved recovery rate, reduced mortality and the likes. The pharmaceutical combination of the present invention can also be used for the continuous care treatment of pets with renal failure.

Abstract: An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R1, R2 independently represent hydrogen atom or halogen atom respectively, and at least one of R1, R2 is halogen atom.

Abstract: Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.

Abstract: A composition includes Mogroside V and a Rebaudioside component in a weight ratio ?1:1 and ?6:1, wherein the Rebaudioside component consists of one or more compounds selected from the group consisting of Rebaudioside A, Rebaudioside B and Rebaudioside D. A method of purifying a Luo Han Guo extract includes contacting the Luo Han Guo extract with activated carbon and a macroporous polymeric adsorbent resin, an ion exchange resin, or both. A composition includes a Luo Han Guo extract, wherein Mogroside V constitutes from 50 wt % to 75 wt % of the Luo Han Guo extract and the composition includes from 0 to 13 wt % in total relative to the Mogroside V of aromatic glycosides, and from 0 to 15 ppm of semi-volatile organic compounds relative to the Mogroside V.

Abstract: A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1?R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.

Abstract: A process for the production of a composition comprising a water-insoluble paracetamol or NSAID which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble paracetamol or NSAID, ii) a water soluble carrier, and iii) a solvent for each of the paracetamol or NSAID and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the paracetamol or NSAID in the carrier.

Abstract: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

Abstract: Disclosed are waving compositions for waving of keratinous fibers, such as hair, containing a) a bisulfite compound, b) a sulfate compound or urea, and c) a phenol, and methods of waving keratinous fibers by applying such compositions to keratinous fibers. Also disclosed is a multi-unit cosmetic kit for treating a keratinous fiber containing a) a first unit containing a first composition containing a bisulfite compound and a sulfate compound or urea, and b) a second unit containing a second composition containing a phenol.

Abstract: The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.

Abstract: The invention is directed to a mixture of esters according to the general formula (I), R1—C(?O)—O—R2, wherein R1 is an alkyl moiety with 7 to 9 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 10 carbon atoms, wherein the mixture comprises 5 to 60 weight-% of ester of the general formula (I), wherein R1 is an alkyl moiety with 9 carbon atoms, based on the total amount of esters according to formula (I) and/or wherein the mixture comprises 5 to 60 weight-% of ester of the general formula (I), wherein R2 is an alkyl moiety with 10 carbon atoms, based on the total amount of esters according to formula (I). The invention is further directed to cosmetic and/or pharmaceutical compositions comprising such esters and processes for the production of such esters.

Abstract: A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders.